Aethlon Medical INC

Aethlon Medical, Inc. announced a 1-for-5 reverse stock split to manage dilution and maintain Nasdaq compliance, effective July 31, 2026.

Aethlon Medical has filed an amendment to its prospectus supplement, allowing for the sale of up to $542,716 in common stock under an existing at-the-market agreement.

Aethlon Medical, Inc. announced that all previously outstanding pre-funded warrants have been exercised, resulting in 1,569,110 shares of common stock outstanding.

Aethlon Medical, Inc. stockholders approved a significant increase in authorized common stock and expanded its equity incentive plan at the Annual Meeting on February 19, 2026.

Aethlon Medical, Inc. announced its fiscal third quarter 2026 financial results, highlighting continued clinical and research program advancements alongside year-to-date cost efficiencies.

Aethlon Medical, Inc. amended agreements with an institutional investor, removing the shareholder approval requirement for pre-funded warrants, making them immediately exercisable.

Aethlon Medical's Q1 2026 Form 10-Q filing details ongoing clinical development for its Hemopurifier, continued net losses, and a recent capital raise.

Aethlon Medical, Inc. reported its Q3 2026 financial results, highlighting progress in its Australian oncology trial and a recent capital raise, while facing ongoing liquidity concerns.

Aethlon Medical reported reduced net losses and advanced its Hemopurifier oncology trial in Australia, while addressing Nasdaq listing compliance and acknowledging ongoing capital needs.

Aethlon Medical, a clinical-stage medical device company, reported a significant cash reduction and issued a going concern warning, despite progress in its Australian oncology trial.

Aethlon Medical's Q3 2025 report details ongoing clinical trials for the Hemopurifier, recent equity transactions, and financial results, while acknowledging the need for additional funding.

Aethlon Medical reports a net loss of $5.37 million for the six months ended September 30, 2024, while advancing clinical trials for its Hemopurifier device.

Aethlon Medical reports progress in its Australian oncology clinical trial while highlighting ongoing going concern risks.

Aethlon Medical, a clinical-stage medical therapeutic company, reported significant operating losses for fiscal year 2025, with auditors raising substantial doubt about its ability to continue as a going concern, despite progress in its Hemopurifier clinical trials and recent capital raises.

Aethlon Medical files an amendment to its annual report to include previously omitted information regarding directors, executive compensation, and corporate governance.

Aethlon Medical's annual report details ongoing efforts in developing the Hemopurifier for cancer and viral infections, while navigating financial challenges and regulatory hurdles.

Director Chetan Shah reported a forfeiture of 2,182 shares of common stock in Aethelon Medical Inc. to cover tax withholdings related to the conversion of restricted stock units.

Director Nicolas Gikakis reported a transaction involving the forfeiture of 2,182 shares of common stock to cover tax withholdings related to the conversion of restricted stock units.

Aethelon Medical Inc. director Edward G. Broenniman reported a transaction involving the forfeiture of 1,091 shares of common stock to cover tax withholdings.

Director Angela Rossetti was granted 21,815 restricted stock units in Aethlon Medical, vesting quarterly through March 2027.

Director Chetan Shah was granted 21,815 restricted stock units in Aethlon Medical, vesting quarterly through March 2027.

Director Edward G. Broenniman acquired 21,815 shares of Aethlon Medical common stock via restricted stock units.

Aethlon Medical, Inc. announced amendments to its Pre-Funded Warrants, making them immediately exercisable, while still seeking shareholder approval for Nasdaq compliance.

Aethlon Medical reports positive safety data and exploratory findings from its Australian oncology trial, advancing to the second cohort, while seeking shareholder approval for significant share authorization increases and warrant exercises to fund ongoing operations.

Aethlon Medical is holding a special meeting to seek stockholder approval for a reverse stock split and the issuance of shares related to inducement warrants.

Aethlon Medical is holding its annual shareholder meeting on September 27, 2024, to vote on director elections, auditor ratification, an equity incentive plan amendment, executive compensation, and meeting adjournment if needed.

Aethlon Medical is holding its annual stockholder meeting on September 27, 2024, to vote on director elections, auditor ratification, an equity incentive plan amendment, executive compensation, and meeting adjournment.

Aethlon Medical, Inc. has filed Amendment No. 2 to its Form S-1 Registration Statement, primarily to include an updated consent from its independent registered public accounting firm.

Aethlon Medical, Inc. has filed an S-1/A registration statement detailing a proposed offering of common stock and warrants, aiming to raise capital for general corporate purposes.

Aethlon Medical, Inc. filed an S-1 registration statement for the resale of up to 2,031,024 shares of common stock underlying various warrants, primarily from a December 2025 private placement.

Aethlon Medical, Inc. filed an S-1/A registration statement for a best-efforts public offering of common stock and warrants to raise capital, while disclosing substantial doubt about its ability to continue as a going concern.

Aethlon Medical, a clinical-stage medical device company, is seeking to raise capital through a best-efforts public offering of common stock and warrants to fund operations, despite significant historical losses and substantial doubt about its ability to continue as a going concern.

Aethlon Medical launches a best-efforts offering of common stock and warrants to fund research, clinical trials, and general corporate activities.

A Schedule 13G filing reveals passive ownership of Aethelon Medical Inc. common stock by Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.

Armistice Capital, LLC and Steven Boyd have jointly reported a beneficial ownership of 4.99% of Aethlon Medical, Inc.'s common stock as of March 31, 2026.

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 4.99% in Aethlon Medical Inc., a reduction that places their stake below the 5% threshold.

Ikarian Capital, LLC and Neil Shahrestani have reported a 2.0% beneficial ownership stake in Aethlon Medical, Inc., totaling 15,366 shares.

Alumni Capital LP and its affiliates have reported a 9.58% beneficial ownership stake in Aethlon Medical Inc., primarily through a Securities Purchase Agreement and warrants.

Intracoastal Capital LLC, along with Mitchell P. Kopin and Daniel B. Asher, reported a 7.7% beneficial ownership stake in Aethlon Medical, Inc. as of September 10, 2025.